Recurrent Ovarian Carcinoma Recruiting Phase 2 Trials for Human interleukin-2 (DB14865)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03610490Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaTreatment